Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
XFOR Stock Forecast 2026-2027
$4.08
Current Price
$384.82M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to XFOR Price Targets
+218.6%
To High Target of $13.00
+194.1%
To Median Target of $12.00
+145.1%
To Low Target of $10.00
XFOR Price Momentum
+6.0%
1 Week Change
+3.6%
1 Month Change
+49.5%
1 Year Change
+2.0%
Year-to-Date Change
-15.5%
From 52W High of $4.83
+202.2%
From 52W Low of $1.35
📊 TOP ANALYST CALLS
Did XFOR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if X4 Pharmaceuticals is one of their latest high-conviction picks.
Latest XFOR Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, XFOR has a bullish consensus with a median price target of $12.00 (ranging from $10.00 to $13.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $4.08, the median forecast implies a 194.1% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XFOR Analyst Ratings
4
Buy
0
Hold
0
Sell
XFOR Price Target Range
Low
$10.00
Average
$12.00
High
$13.00
Current: $4.08
Latest XFOR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XFOR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 2, 2026 | Leerink Partners | Thomas Smith | Outperform | Initiates | $12.00 |
| Mar 9, 2026 | Guggenheim | Buy | Initiates | $N/A | |
| Dec 5, 2025 | Stifel | Buy | Maintains | $N/A | |
| Nov 10, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 29, 2025 | Stifel | Buy | Maintains | $N/A | |
| Aug 13, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 2, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 27, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 26, 2025 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Feb 7, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 14, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 14, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 14, 2024 | Stifel | Buy | Maintains | $N/A | |
| Jun 28, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 31, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Apr 30, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 22, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 12, 2023 | B. Riley Securities | Neutral | Downgrade | $N/A | |
| Aug 11, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 17, 2023 | Stifel | Buy | Maintains | $N/A |
X4 Pharmaceuticals Inc. (XFOR) Competitors
The following stocks are similar to X4 Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
XFOR
X4 Pharmaceuticals
mkt cap
377.28M
X4 Pharmaceuticals Inc. (XFOR) Financial Data
X4 Pharmaceuticals Inc. has a market capitalization of $384.82M with a P/E ratio of 0.7x. The company generates $9.01M in trailing twelve-month revenue with a 83.6% profit margin.
Revenue growth is -90.6% quarter-over-quarter, while maintaining an operating margin of -748.5% and return on equity of -104.2%.
Valuation Metrics
Market Cap
$384.82M
Enterprise Value
$228.36M
P/E Ratio
0.7x
PEG Ratio
0.0x
Price/Sales
42.7x
Growth & Margins
Revenue Growth (YoY)
-90.6%
Gross Margin
+77.9%
Operating Margin
-748.5%
Net Margin
+83.6%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+60.7%
Current Ratio
10.2x
Debt/Equity
45.9x
ROE
-104.2%
ROA
-28.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
X4 Pharmaceuticals Inc. (XFOR) Business Model
About X4 Pharmaceuticals Inc.
What They Do
Develops therapeutics for rare immune diseases.
Business Model
X4 Pharmaceuticals generates revenue by researching, developing, and commercializing unique biopharmaceutical products, particularly focusing on rare diseases. The company is advancing its lead product, mavorixafor, through clinical trials, which may lead to sales upon successful commercialization and approval in various indications.
Additional Information
The company is headquartered in Boston, Massachusetts, and is actively involved in a Phase 3 clinical trial to evaluate the safety and efficacy of mavorixafor for chronic neutropenia. Additionally, it holds license agreements for the drug's development in oncology and international markets, potentially expanding its revenue streams.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
143
CEO
Dr. Paula Ragan Ph.D.
Country
United States
IPO Year
N/A
Website
www.x4pharma.comX4 Pharmaceuticals Inc. (XFOR) Latest News & Analysis
Latest News
Quick Summary
X4 Pharmaceuticals issued inducement awards of 160,000 stock options to new employees under its 2019 Inducement Plan, effective May 29, 2026, as approved by its Compensation Committee.
Why It Matters
The issuance of inducement awards signals X4 Pharmaceuticals' commitment to attracting talent, potentially enhancing innovation and growth, which can positively impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
X4 Pharmaceuticals will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 3:45 p.m. ET. Webcast available on their website.
Why It Matters
X4 Pharmaceuticals' presentation at a major healthcare conference could signal potential developments in their treatments, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), indicating increasing optimism about its earnings prospects.
Why It Matters
X4 Pharmaceuticals' upgrade to a Zacks Rank #2 signals strong earnings potential, likely boosting investor confidence and driving stock prices higher.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
X4 Pharmaceuticals (XFOR) shows a hammer chart pattern, suggesting support after recent declines, alongside rising earnings estimate revisions, indicating a potential trend reversal.
Why It Matters
The hammer chart pattern signals potential reversal and support for X4 Pharmaceuticals, while rising earnings estimates suggest improving fundamentals, indicating possible stock recovery.
Source: Zacks Investment Research
Market Sentiment:
Negative
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
1 month ago
Quick Summary
X4 Pharmaceuticals (Nasdaq: XFOR) expects to complete enrollment for its 4WARD Phase 3 trial by Q3 2026. It received EU approval for XOLREMDI® for WHIM Syndrome and has cash to operate through 2028.
Why It Matters
X4 Pharmaceuticals' trial progress and EU approval for mavorixafor enhance its market position, potentially boosting revenue and investor confidence, while a solid cash runway supports operational stability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
X4 Pharmaceuticals (XFOR) reported a quarterly loss of $0.16 per share, beating the Zacks estimate of $0.20. This is a decline from earnings of $0.04 per share a year prior.
Why It Matters
X4 Pharmaceuticals' narrower-than-expected loss may indicate improving financial performance, potentially boosting investor confidence and impacting stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About XFOR Stock
What is X4 Pharmaceuticals Inc.'s (XFOR) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, X4 Pharmaceuticals Inc. (XFOR) has a median price target of $12.00. The highest price target is $13.00 and the lowest is $10.00.
Is XFOR stock a good investment in 2026?
According to current analyst ratings, XFOR has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.08. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XFOR stock?
Wall Street analysts predict XFOR stock could reach $12.00 in the next 12 months. This represents a 194.1% increase from the current price of $4.08. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is X4 Pharmaceuticals Inc.'s business model?
X4 Pharmaceuticals generates revenue by researching, developing, and commercializing unique biopharmaceutical products, particularly focusing on rare diseases. The company is advancing its lead product, mavorixafor, through clinical trials, which may lead to sales upon successful commercialization and approval in various indications.
What is the highest forecasted price for XFOR X4 Pharmaceuticals Inc.?
The highest price target for XFOR is $13.00 from at , which represents a 218.6% increase from the current price of $4.08.
What is the lowest forecasted price for XFOR X4 Pharmaceuticals Inc.?
The lowest price target for XFOR is $10.00 from at , which represents a 145.1% increase from the current price of $4.08.
What is the overall XFOR consensus from analysts for X4 Pharmaceuticals Inc.?
The overall analyst consensus for XFOR is bullish. Out of 2 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are XFOR stock price projections?
Stock price projections, including those for X4 Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 9:20 AM UTC